You probably think “antibiotic resistance” means that a bacterial infection can’t be cured by any antibiotics. But the FDA ...
How likely is flu-related pneumonia to happen to you? What are the symptoms to look out for when they can be similar to those ...
A sore throat usually isn't serious enough for a trip to the doctor, and many natural remedies can help ease your symptoms, ...
By combining MERFISH imaging with expansion microscopy, researchers have unlocked a new way to study bacteria at the ...
Sepsis, a life-threatening organ dysfunction, is responsible for an estimated 1 in 5 deaths globally and 1 in 3 deaths that ...
GlobalData on MSN19h
FDA approves AbbVie’s Emblaveo for intra-abdominal infectionsAbbVie has received US Food and Drug Administration (FDA) approval for Emblaveo (aztreonam and avibactam) to be used in ...
AbbVie receives US FDA approval for Emblaveo to treat adults with complicated intra-abdominal infections with limited or no treatment options: North Chicago, Illinois Monday, Febr ...
Emblaveo will be available in the third quarter of 2025 to treat patients with intra-abdominal infections, a common cause of sepsis in the intensive care unit.
The intravenous antibiotic Emblaveo, a combination of aztreonam and avibactam approved in Europe last year, was developed in ...
Pfizer’s contributions to animal health date back several decades, during which the company played a significant role in ...
Addresses the significant threat of antimicrobial resistance.
Emblaveo (aztreonam-avibactam) was approved for treating complicated intra-abdominal infections with limited or no treatment options.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback